Combined treatment of patients with lower urinary tract symptoms and erectile. dysfunction


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In men of middle and older age group, urination disorders and erectile dysfunction are often combined. The role of phosphodiesterase type 5 inhibitors in the treatment of these patients remains uninvestigated. Prospective study included 38 patients with urination disorders and erectile dysfunction. The average age of the patients was 63,6±5,3 years. During first three months of observation, all patients have received alpha-adrenoblocker doxazosin at a dose of 4 mg once daily per os, the next three months - phosphodiesterase type 5 inhibitor udenafil at a dose of 50 mg once daily per os was added to doxazosin. 3 months after treatment, majority of patients reported improvement of urination. The statistically significant changes in BP and heart rate were not recorded, indicating a satisfactory tolerability and safety of doxazosin. Against the background of combined treatment during next 3 months, progressive improvement of erectile function (IIEF score 12,8±3,4 vs 18,4±3,7; p<0,05), and regression of urination disorders, according to IPSS score (13,4±1,2 vs 11,2±1,7; p<0,05) were observed. Uroflowmetric indicators were not significantly changed. Based on experimental and clinical studies, it was suggested that the dysregulation of NO - cGMP system, pathological activation of Rho-kinase pathways, hyperactivity of autonomic innervation, atherosclerosis and impaired blood flow in the pelvic organs are the common pathophysiological mechanisms for LUTS and erectile dysfunction. The clinical efficacy of phosphodiesterase type 5 inhibitors in the treatment of patients with these diseases is explained by its effects on these mechanisms.

Full Text

Restricted Access

References

  1. Seftel A.D., de la Rosette J., Birt J. et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int. J Clin. Pract. 2013;67(1):32-33.
  2. McVary K.T., Monnig W., Camps J.L. Jr, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007; 177(3): 1071-1077.
  3. Stief C.G., Porst H., Neuser D., Beneke M. et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur. Urol. 2008; 53(6): 1236-1244.
  4. Kedia G.T., Uckert S., Jonas U. et al. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol. 2008;26:603-609.
  5. Fibbi B., Morelli A., Vignozzi L. et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010;7:59-69.
  6. Morelli A., Filippi S., Sandner P. et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med. 2009;6:1594-1608.
  7. Rahman N.U., Phonsombat S., Bochinski D. et al. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidemic rat. BJI Int. 2007;100:658-663.
  8. Ronholzer A., Temml C., Wehrberger C. et al. The association between LUTS and vascular risk factor both sexes. Eur. Urol. 2006; 50: 581-586.
  9. Montorsi P., Ravagnani P.M., Galli S. et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur. Urol. 2006;50:721-731.
  10. Penna G., Fibbi B., Amuchastegui S. et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009;69:480-493.
  11. Corona G., Maggi M. The role of testosterone in erectile dysfunction. Nat. Rev. Urol. 2010;7:46-56.
  12. Madersbacher S., Marszalek M., Lackner J. et al. The long-term outcome of medical therapy for BPH. Eur. Urol. 2007;51(6):1522-1533.
  13. Van Dijk M.M., De La Rosette J.J., Michel M.C. Effects of alpha 1 adrenoceptor antagonists on male sexual function. Drugs. 2006; 66:287-301.
  14. Kirby R.S., O’Leary M.P., Carson C. Efficacy of extended release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int. 2005;95:103-109.
  15. Kirby R.S., Roehrborn C., Boyle P. et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003; 61: 119-126.
  16. Bella A.J., DeYoung L.X., al-Numi M. et al. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur. Urol. 2007;52:990-1005.
  17. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292-300.
  18. Porst H., Giuliano F., Glina S. et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double blind, placebo-controlled trial. Eur. Urol. 2006;50:351-359.
  19. Salem E.A., Kendirci M., Hellstrom W.J. Udenafl, a long-acting PDE5 inhibitor for erectile dysfunction. Curr. Opin. Investig Drugs. 2006;7:661-669.
  20. Zhao C., Kim S.H., Lee S.W. et al. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011;107:1943-1947.
  21. Morelli A., Chavalmane A.K., Filippi S. et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signalling hyperactivation. J Sex Med. 2009;6:91-106.
  22. Bertolotto M., Trincia E., Zappetti R. et al. Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol Med. 2009;114: 1106-1114.
  23. Stief C.G., Porst H., Neuser D. et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur. Urol. 2008;53:1236-1244.
  24. Chung B.H., Lee J.Y., Lee S.H. et al. Safety and efficacy of the simultaneous administration of udenafil and an alphablocker in men with erectile dysfunction concomitant with BPH/LUTS. Int. J Impot. Res. 2009;21:122-128.
  25. Tuncel A., Nalcacioglu V., Ener K. et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapyin treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010;28:17-22.
  26. Speakman M.J. PDE5 inhibitors in the treatment of LUTS. Curr. Pharm. Des. 2009;15:3502-505.
  27. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr. Opin. Urol. 2010;20:49-54.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies